TScan Therapeutics, Inc. reported positive initial data from Cohort C of its ALLOHA Phase 1 study evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation. Among 19 enrolled patients, the company achieved a ~90% manufacturing success rate and 11 of 14 patients who underwent transplant received complete donor chimerism within approximately three weeks of their first infusion. TScan Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for patients with hematologic malignancies.
